Literature DB >> 9385753

Transdermal clonidine in the prophylaxis of episodic cluster headache: an open study.

M Leone1, A Attanasio, L Grazzi, G Libro, D D'Amico, F Moschiano, G Bussone.   

Abstract

Transdermal clonidine has recently been reported to be efficacious in the prophylaxis of cluster headache. A 2-week course of transdermal clonidine (5 mg the first week, 7.5 mg the second week) preceded by a 5-day run-in period, was administered to 16 patients with episodic cluster headache in an active cluster period. In 5 patients, the painful attacks disappeared after the seventh day of treatment. For the group as a whole, no significant variations in headache frequency, pain intensity, or attack duration were observed between the run-in period and the first and second weeks of treatment (ANOVA). Further studies are necessary to clarify the effectiveness of transdermal clonidine in the prophylaxis of episodic cluster headache.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385753     DOI: 10.1046/j.1526-4610.1997.3709559.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

1.  Cluster Headache.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 2.  Management of trigeminal autonomic cephalgias and hemicrania continua.

Authors:  Manjit S Matharu; Christopher J Boes; Peter J Goadsby
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  The use of baclofen in cluster headache.

Authors:  R Hering-Hanit; N Gadoth
Journal:  Curr Pain Headache Rep       Date:  2001-02

4.  Transdermal clonidine: therapeutic considerations.

Authors:  Domenic A Sica; Rebecca Grubbs
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

Review 5.  The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias.

Authors:  Alfredo Costa; Fabio Antonaci; Matteo Cotta Ramusino; Giuseppe Nappi
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.